2021
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial
Sharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George JT, Hantel S, Desai N, Mentz RJ. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial. JACC Heart Failure 2021, 9: 568-577. PMID: 34325887, DOI: 10.1016/j.jchf.2021.03.003.Peer-Reviewed Original ResearchConceptsCV deathLatent class analysisTreatment effectsNon-coronary artery diseaseEMPA-REG OUTCOME trialAdvanced coronary diseaseEMPA-REG OUTCOMESGLT-2 inhibitionGlomerular filtration rateType 2 diabetesEMPA-REGEmpagliflozin 25CV diseaseCV riskLower eGFRT2D durationOlder patientsOutcome trialsYounger patientsArtery diseaseCoronary diseaseCox regressionFiltration rateCardiovascular diseaseGroup 2
2020
1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
SHARMA A, OFSTAD A, AHMAD T, ZINMAN B, ZWIENER I, FITCHETT D, WANNER C, GEORGE J, HANTEL S, DESAI N, MENTZ R. 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1144-p.Peer-Reviewed Original ResearchCV deathNovartis Pharmaceuticals CorporationPhenotype of patientsTreatment effectsEli LillyEMPA-REG OUTCOMERisk of outcomesType 2 diabetesAdvisory PanelBoehringer Ingelheim PharmaceuticalsBristol-Myers SquibbEMPA-REGMundipharma InternationalSanofi GenzymeCardiovascular deathCV diseaseT2D durationOlder patientsYounger patientsHeart failureAtherosclerotic diseaseSGLT2 inhibitionCox regressionDohme Corp.Patients